Corcept Therapeutics Incorporated
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes drugs modulating cortisol activity at the glucocorticoid receptor to treat severe metabolic, oncologic, psychiatric and endocrine disorders. The company markets Korlym (mifepristone), the first FDA-approved treatment for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery; Korlym is available through a limited network of specialty pharmacies with patient support programs including financial assistance. Corcept advances a pipeline of proprietary selective cortisol modulators, including relacorilant in Phase 3 for Cushing's syndrome (PDUFA target date December 30, 2025) and in Phase 3 ROSELLA trial combined with nab-paclitaxel for platinum-resistant ovarian cancer (PDUFA target date July 11, 2026), where it demonstrated improved progression-free and overall survival in October 2025 ASCO late-breaker data; nenocorilant in Phase 1b with nivolumab for solid tumors; and other candidates targeting antipsychotic-induced weight gain, NASH, triple-negative breast cancer, castration-resistant prostate cancer, endometrial cancer, cervical cancer and platinum-sensitive ovarian cancer post-PARP inhibitor progression. Founded in 1998 and headquartered in Redwood City, California, the company conducts operations primarily in the United States and pursues global regulatory submissions including in Europe. Recent developments include Q3 2025 revenue of $207.6 million versus $182.5 million in Q3 2024, lifted full-year 2025 revenue guidance, initiation of new BELLA trial arms for relacorilant plus nab-paclitaxel with bevacizumab in platinum-sensitive ovarian cancer and in endometrial cancer, a Phase 2 collaboration with Arcagy Research for relacorilant plus nab-paclitaxel in cervical cancer, an ongoing transition to a new specialty pharmacy for Korlym fulfillment, and expansion of over 30 studies across endocrinology, oncology, metabolism and neurology.
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors
Why Crinetics Stock Soared 99% This Week
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?